

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT

“ELTROMBOPAG OLAMINE TABLETS” APPROVED FOR MARKETING

The board of directors (the “**Board**”) of Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Eltrombopag Olamine Tablets” (Trade name: Aifusheng* (艾复生)) developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Group, has obtained the approval for marketing from the National Medical Products Administration of China (NMPA) for use in adults and children aged 6 years and above patients with chronic immune (idiopathic) thrombocytopenia (ITP), who have not responded well to previous treatment with glucocorticoids and immunoglobulins, so as to increase platelet count and reduce or prevent bleeding. This product is only used for ITP patients who have an increased risk of bleeding due to thrombocytopenia and clinical conditions.

Eltrombopag Olamine Tablet is an oral, small molecule, non-peptide thrombopoietin receptor agonist (TPO-RA) that acts to increase the number of platelets. In the “Chinese Guidelines for Treatment of Adult Primary Immune Thrombocytopenia (2020 edition)”, eltrombopag is the only drug with the highest level (1a) of evidence and Class A recommendation, and it is also the only thrombopoietic drug approved for the indication of ITP in children over 6 years old in China.

Compared with other ITP drugs, eltrombopag olamine tablets has the following advantages:

1. Rapid onset of action: With an onset of action of 1 to 2 weeks, this drug is effective for severe ITP patients to increase platelet counts rapidly and reduce occurrence of bleeding;
2. Stronger response and high efficacy: Regardless of whether used for short-term or long-term treatment of ITP, it can significantly increase platelet count and reduce bleeding symptoms;
3. Long-term relief through personal and continuous medication, which in turn improving quality of life;

4. Convenient medication and high compliance: Simple and convenient oral administration. There is no need to be taken on an empty stomach, which removes the restriction of consuming food before administration and greatly improves medication compliance;
5. Higher level of safety for long-term medication;
6. Drugs explicitly approved for the treatment of pediatric chronic ITP in the specification: Currently, among the seven drugs approved by the NMPA for the treatment of chronic ITP, eltrombopag olamine tablets is the drug explicitly approved for the treatment of pediatric indications in the specification.

In addition, TPO drugs can also be combined with rituximab to treat glucocorticoid-refractory or relapsed ITP patients, with a higher efficiency in general. Based on the aforementioned advantages, TPO drugs become the first choice for second-line ITP treatment.

Aifusheng has the same dosage form as the brand-name drug, and the bioequivalence of Aifusheng with the reference preparation has been fully confirmed through fasting and postprandial human bioequivalence tests. The approval of Aifusheng will further enrich the treatment options for ITP patients, reduce treatment costs, ease the economic pressure of medication on patients, and contribute to the development of pediatric medication in China. The Company will continue to launch clinically necessary, high-quality and economical drugs to bring good news to the vast population of patients in the future.

By Order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Changcheng
Chairman and Executive Director

Hong Kong, 21 October 2024

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming (formerly known as Mr. Cao Dudu) as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.

** For identification purposes only*